MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Bioserve Biotechnologies Unveils PreciOnc: Revolutionizing At-Home Genetic Testing for Cancer Risk

NextEdge Admin

26 Sep 2024

2 min 24 sec

Bioserve Biotechnologies (India) Pvt. Ltd., a REPROCELL company, proudly announces the launch of PreciOnc, a groundbreaking at-home genetic testing service for assessing hereditary cancer risk, including breast cancer. With PreciOnc, individuals can easily evaluate their genetic risk from home without the need for doctor referrals or invasive blood tests.

PreciOnc offers two comprehensive services: PreciOnc-Presight, which assesses genetic risk for hereditary cancers like breast cancer by analyzing key genes such as BRCA1 and BRCA2, and PreciOnc-Inheritica, which extends the analysis to include additional genetic markers linked to other cancers, such as ovarian and colorectal cancer. This holistic approach allows individuals to gain valuable insights into their hereditary cancer risks across a wide spectrum.

The testing process is user-friendly and convenient. Customers can order their PreciOnc genetic testing kit online, without requiring a prescription. Using a saliva collection kit, they can provide a sample from the comfort of their home by following simple instructions. The sample is then returned to Bioserve's state-of-the-art laboratories using a prepaid shipping label. Once analyzed, a comprehensive genetic report is delivered, outlining the individual’s cancer risk and offering actionable insights for proactive health management.

As part of Bioserve’s dedication to advancing personalized medicine, PreciOnc makes genetic testing more accessible and empowers individuals to take control of their health. With over 20 years of experience in molecular services, Bioserve Biotechnologies, part of the global REPROCELL Group, continues to deliver high-quality biotechnological solutions to clients in India and beyond.